Skip to main content

Posts

Showing posts with the label pfizer

Pain Research

From King's College London: Innovative Partnership for Pain Research 10 Mar 2010, PR 48/10 "King’s has partnered with Pfizer to create an open innovation laboratory for pain research. As part of the partnership, a small team of Pfizer scientists will be based at the Wolfson Centre for Age-Related Diseases to conduct research in pain biology." read the full article
Post a Comment
Read more

Alzheimer Disease: Dimebon Results, Part II

From The New York Times : Hopes for Alzheimer’s Drug Are Dashed By ANDREW POLLACK Published: March 4, 2010 "The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer." Read the full article
Post a Comment
Read more

Alzheimer Disease: Dimebon Results

A press release from earlier today by Pfizer: Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program [snip] "About the CONNECTION Study "CONNECTION is a Phase 3, multi-national, double-blind, placebo-controlled safety and efficacy trial involving 598 patients with mild-to-moderate AD at 63 sites in North America, Europe, and South America. Patients had a mean age of 74.4 years and a mean score of 17.7 on the Mini-Mental State Examination (MMSE) upon entry into the study. More than 40 percent of the patients enrolled were in the United States. In the study, patients were randomized to one of three treatment groups, receiving dimebon 20 mg three times a day (TID), dimebon 5 mg TID, or placebo TID for six months. The 5 mg arm was included in the study to help define the effective dose range for dimebon treatment. "No statistically significant improvements for the 20 mg TID group relative to ...
Post a Comment
Read more